$18.22
30.50% day before yesterday
Nasdaq, May 30, 10:17 pm CET
ISIN
US86627R1023
Symbol
SMMT
Sector
Industry

Summit Therapeutics PLC Sponsored ADR Stock price

$18.22
-5.91 24.48% 1M
-0.28 1.49% 6M
+0.37 2.07% YTD
+7.30 66.80% 1Y
+17.11 1,540.99% 3Y
+14.51 390.97% 5Y
+7.52 70.26% 10Y
Nasdaq, Closing price Fri, May 30 2025
-8.00 30.50%
ISIN
US86627R1023
Symbol
SMMT
Sector
Industry

Key metrics

Market capitalization $13.53b
Enterprise Value $13.17b
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 39.23
Free Cash Flow (TTM) Free Cash Flow $-173.70m
Cash position $361.32m
P/E forward negative
Short interest 22.06%

Is Summit Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy
100%

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
61% 61%
-
- Research and Development Expense 120 120
79% 79%
-
-169 -169
72% 72%
-
- Depreciation and Amortization 0.09 0.09
55% 55%
-
EBIT (Operating Income) EBIT -169 -169
72% 72%
-
Net Profit -178 -178
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Summit Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Summit Therapeutics PLC Sponsored ADR Stock News

Negative
Seeking Alpha
2 days ago
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market ...
Negative
The Motley Fool
2 days ago
Shares of Summit Therapeutics (SMMT -27.85%) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.
Positive
Barrons
2 days ago
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Robert Zanganeh
Employees 159
Founded 2003
Website www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today